Mira Kyivska

Injective falls over 15% as sellers intensify despite Veyra upgrade vote progress

Injective falls over 15% as sellers intensify despite Veyra upgrade vote progress
Injective slides 15.18% today to $6.79

Injective (INJ) slid 15.18% after sellers intensified their activity, even as governance voting for the major Veyra network upgrade advanced with strong community support. The down move is supported by the asset trading below both the 20-day and 50-day moving averages, indicating persistent short- and medium-term pressure.

INJ price prediction
24H -8.88%
$5.54
48H -10.53%
$5.44
7D -21.71%
$4.76
1M -11.35%
$5.39
3M -63.98%
$2.19
6M -77.14%
$1.39
12M 26.97%
$7.72
Current price: $6.08 -0.57 8.59%
Real-time Data 07:44
Daily range 5.85 Arrow from to Icon 6.39
Weekly range 5.99 Arrow from to Icon 7.74
Loading...

Highlights

  • Injective began its final major network upgrade for 2026, named Veyra, with over 13 million INJ staked and more than 60% community approval by mid-November.
  • The Veyra upgrade introduces institutional-grade RWA infrastructure, RFQ systems, new cross-chain features, and CypherOS foundations, while Injective Institutional Services registered as an SEC transfer agent and a staked INJ ETF launched on Nasdaq.
  • INJ/USD trades below short-term moving averages but above the 200-day, with mixed momentum indicators and an expected range of $5.99 to $7.44 over the next five days.

Network upgrade momentum persists despite investor selling pressure

Injective initiated its final major network upgrade for 2026, named Veyra, with governance voting underway for Proposal IIP-717 and over 13 million INJ staked and more than 60% of community support reported by mid-November. The Veyra upgrade, scheduled for activation on November 24, includes new institutional-grade RWA infrastructure, RFQ systems, cross-chain capabilities via IBC, and foundational components for CypherOS. Injective Institutional Services registered as an SEC transfer agent and Canary Capital launched a staked INJ ETF (INJC) on Nasdaq, accompanied by ongoing efforts to migrate USDC tokens across Cosmos and dYdX to standardize stablecoin usage, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views the recent 15.18% decline in INJ as a strong warning signal. He points to persistent price weakness below both the 20-day and 50-day moving averages, which keeps momentum slanted to the downside. Continued selling pressure despite positive news, such as institutional adoption and SEC registration, highlights a critical lack of broader market confidence. Technical indicators, while mixed, offer little evidence of a robust trend reversal in the short term. "Until INJ establishes support above $7.44 and overcomes heavy selling, I would remain skeptical about any near-term bullish case for this asset," says Kharitonov.
Viktoras Karapetjanc, expert at Traders Union, maintains a confident outlook on INJ’s prospects. He emphasizes strong community support for the Veyra upgrade and regulatory milestones, seeing these as reinforcing long-term value. The bullish structure remains intact above the 200-day moving average, and ongoing network developments set the basis for further institutional growth. Karapetjanc believes the present consolidation offers opportunity for accumulation. "With foundational upgrades taking effect and sentiment improving, I expect further growth as the market gradually re-prices INJ’s real achievements," he affirms.
Sholanke Dele, market strategist, is cautious on INJ. He notes a disconnect between positive project news and recent price performance, which signals skepticism among traders. Dele warns that lack of a clear trend and high volatility increase short-term risk. "Unless buyers sustain momentum above resistance, I see little justification for optimism in the current setup," he states.
Injective asset chart
Injective price dynamics. Source: TradingView.

Mixed technical signals as short-term weakness faces lingering bullish trend

INJ/USD is trading below the 20-day and 50-day moving averages at $7.76 and $7.82, but remains above the 200-day at $5.8. Short- and medium-term momentum is under pressure from sellers, while the longer-term trend maintains a bullish bias according to moving average alignment. The near-term resistance is at $7.04, with support at $5.99. Momentum signals are mixed: the MACD suggests buying momentum, but the ADX at 12.4 points to a lack of a strong trend. Both the RSI and CCI are neutral, while the Stochastic RSI is overbought. Bull/Bear Power shows buyers dominating intraday, but price is currently near session lows with volatility at 17.19%, highlighting strong seller dominance following an upside gap at the open.

Previously it was reported that Injective's price action was guided by strong institutional engagement and active governance around ecosystem upgrades, with technical indicators suggesting the need to monitor key support and resistance for breakout validation. With current price consolidation amid the rollout of the Veyra upgrade and new institutional onramps, traders should watch for a decisive move above $7.44 to confirm a renewed bullish trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.